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Sherif S. Farag,1 Kati Maharry,2,3 Mei-Jie Zhang,4 Waleska S. Perez,4 Stephen L. George,3
Krzysztof Mrozek,2 John DiPersio,5 Donald W. Bunjes,6 Guido Marcucci,2 Maria R. Baer,7
Mitchell Cairo,8 Edward Copelan,9 Corey S. Cutler,10 Luis Isola,11 Hillard M. Lazarus,12
Mark R. Litzow,13 David I. Marks,14 Olle Ringden,15 David A. Rizzieri,16 Robert Soiffer,10
Richard A. Larson,17 Martin S. Tallman,18 Clara D. Bloomfield,2 Daniel J. Weisdorf,19 on
behalf of the Acute Leukemia Committee of the Center for International Blood and Marrow
Transplant Research and Cancer and Leukemia Group BWe compared the outcomes of patients age 60-70 years with acute myelogenous leukemia receiving
reduced-intensity allogeneic hematopoietic cell transplantation (HCT) in first remission (CR1) reported
to the Center for International Blood and Marrow Research (n5 94) with the outcomes in patients treated
with induction and postremission chemotherapy on Cancer and Leukemia Group B protocols (n 5 96). All
patients included had been in CR1 for at least 4 months. The HCTrecipients were slightly younger than the
chemotherapy patients (median age, 63 years vs 65 years; P\.001), but there were no significant between-
group differences in the proportion with therapy-related leukemia or in different cytogenetic risk groups.
Time from diagnosis to CR1 was longer for the HCT recipients (median, 44 days vs 38 days; P 5 .031).
Allogeneic HCTwas associated with significantly lower risk of relapse (32% vs 81% at 3 years; P\ .001),
higher nonrelapse mortality (36% vs 4% at 3 years; P \ .001), and longer leukemia-free survival
(32% vs 15% at 3 years; P 5 .001). Although overall survival was longer for HCT recipients, the difference
was not statistically significant (37% vs 25% at 3 years; P 5 .08). Our findings suggest that reduced-
intensity conditioning allogeneic HCT in patients age 60-70 with acute myelogenous leukemia in CR1
reduces relapse and improves leukemia-free survival. Strategies that reduce nonrelapse mortality may yield
significant improvements in overall survival.
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The outcomes of patients age 60 years and older
with acute myeloid leukemia (AML) treated with
conventional cytotoxic chemotherapy remain poor,
with few long-term survivors, irrespective of the induc-
tion chemotherapy provided and the intensity or dura-
tion of postremission treatment [1-5]. Immunologic
therapy in the form of allogeneic hematopoietic cell
transplantation (HCT) performed in first complete
remission (CR1) may offer a potential advantage in
terms of leukemia-free survival (LFS) and overall sur-
vival (OS) in patients with adverse prognostic features
[6-9] and those at intermediate risk [10], due, at least
in part, to a graft-versus-leukemia (GVL) effect.
Although the reported nonrelapse mortality after
allogeneic HCT using myeloablative regimens is ap-
proximately 20%, previous studies have rarely included
patients over age 60 years. For older patients with AML
in CR1, the toxicity associated with myeloablative
conditioning generally precludes the use of this condi-
tioning with allogeneic HCT. Reduced-intensity
conditioning (RIC) regimens with allogeneic HCT
have been better tolerated in older patients, with
acceptable nonrelapse mortality [11-13].
Compared with myeloablative regimens, RIC
before allogeneic HCT is associated with lower nonre-
lapse mortality [14]. A recent Center for International
Blood and Marrow Research (CIBMTR) study of RIC
regimens in more than 500 patients with AML in CR1
found similar outcomes in patients from age 40 up to
age .70 years [15]. Other reported results using this
approach are also encouraging [12-14,16,17] and
suggest that RIC allogeneic HCT may improve the
long-term outcomes in older patients with AML.
As suggested by a prospective feasibility analysis
[18], however, it is possible that older patients with
AML undergoing RIC allogeneic HCTmay be highly
selected for better performance status and expected
tolerance of the transplant-associated toxicity. There-
fore, whether broad application of HCT in the older,
high-risk population will substantially improve out-
come remains uncertain. To date, no prospective stud-
ies comparing RIC allogeneic HCTwith conventional
chemotherapy in older patients with AML in CR1
have been reported. Here we report a comparison of
RIC allogeneic HCT in patients with AML age 60-70
years reported to the CIBMTR with contemporaneous
patients with AML treated with chemotherapy alone on
Cancer and Leukemia Group B (CALGB) protocols.MATERIALS AND METHODS
Inclusion Criteria
The study population included 94 patients with
AML who received RIC allogeneic HCT and werereported to the CIBMTR between January 1999 and
December 2005, and 96 patients with AML who
were treated with multidrug induction and postremis-
sion chemotherapy after enrollment on CALGB
protocols 9720 [19] and 10201 [20] between January
1998 and October 2006. Patients were eligible for
inclusion if they were age 60-70 years, had de novo
or treatment-associated AML or AML evolving from
a previous myelodysplastic or myeloproliferative dis-
order and had achieved CR1, and had not undergone
allogeneic HCT at any point in their subsequent
disease course. Patients with AML-M3 were excluded.
In addition, for CIBMTR cases, only patients who had
received an RIC preparative regimen before related or
unrelated peripheral blood or bone marrow stem cell
transplantation in CR1 were included. Patients receiv-
ing umbilical cord blood grafts were excluded. To
minimize time to transplantation selection bias, the
analysis was limited to patients who remained in
CR1 for at least 4 months. The preparative regimen
was considered RIC if it included a combination of
the following: total body irradiation (TBI)\500 cGy
in a single dose or\800 cGy if fractionated, and/or
nonmyeloablative doses of chemotherapy (total dose
of busulfan #9 mg/kg or melphalan #150 mg/m2).
For nontransplantation (CALGB) cases, patients re-
ceived induction chemotherapy with daunorubicin
and cytarabine (with or without etoposide) and post-
remission chemotherapy according to previously
reported protocols [19]. Cytogenetic analyses for
CALGB cases were centrally reviewed, whereas those
of CIBMTR cases were as reported by the treating
institutions. Cases were classified according to the
cytogenetic risk categories recently proposed by a
consensus panel [20], with no consideration given to
molecular leukemia phenotyping, which was unavail-
able for the majority of patients.Definitions of Clinical Endpoints
For this study, CR1 was defined as achievement
of bonemarrowwith\5% blasts after 1 or more cycles
of induction chemotherapy. For transplantation
(CIBMTR) cases, marrow cellularity and recovery of
blood counts were not considered in the definition of
CR1, whereas for chemotherapy (CALGB) cases,
recovery of blood counts was required for CR1, as
defined previously [21]. Also for chemotherapy cases,
patients who failed to achieve CR after 2 cycles of in-
duction treatment were considered primary refractory
regardless of whether or not they achieved CR with
later salvage chemotherapy, and were excluded from
this analysis. Patients who underwent transplantation
were included if they were in CR1 regardless of the
number of lines of treatment needed to achieve remis-
sion, because the number of induction courses re-
quired to achieve CR1 was not consistently captured
1798 Biol Blood Marrow Transplant 17:1796-1803, 2011S. S. Farag et al.in this group. Relapse was defined as .5% blasts in
a bone marrow aspirate or the development of extra-
medullary leukemia in patients with previously docu-
mented CR. In both patient groups, survival times
were measured from the date of CR1 until either
relapse or death (LFS), or death censoring for patients
alive at last follow-up (OS). After allogeneic HCT,
engraftment was defined as an absolute neutrophil
count (ANC) $500/mL for 3 consecutive days. Grade
II-IV acute graft-versus-host disease (GVHD) was
determined in all patients who underwent transplanta-
tion [22], and chronic GVHD in the subpopulation
who survived for 90 days or longer [23]. In both
groups, nonrelapse mortality was defined as death
during continuous CR1.
Statistical Analysis
Characteristics of the transplantation and chemo-
therapy groups were compared using the Fisher exact
test for categorical variables and theWilcoxon 2-sample
test for continuous variables. The outcome data in
this study are left-truncated. At each time point, the
risk set in the chemotherapy group consisted of all
patients still under study, whereas the risk set in the
transplantation group consisted of those whose time
to transplantation was less than the time point and
who were still on the study. Univariate probabilities
of OS and LFS were calculated using a left-truncated
version of the Kaplan-Meier estimator [24] with 95%
confidence intervals (CIs). Relapse and nonrelapse
mortality were calculated using left-truncated versions
of cumulative incidence curves to accommodate com-
peting risks. Left-truncated Cox proportional hazards
regression models were used to evaluate the relative
risk of patients receiving chemotherapy versus those
receiving HCT. The proportionality assumption was
tested by adding a time-dependent covariate. The pro-
portionality assumption held up for all outcome end-
points. All statistical analyses were performed using
SAS version 9.2 (SAS Institute Inc, Cary, NC).RESULTS
Patients
The demographic characteristics of the transp-
lantation group (n 5 94) and chemotherapy group
(n 5 96) are shown in Table 1. The patients in the
transplantation group were slightly, but significantly,
younger than those in the chemotherapy group
(median age, 63 years vs 65 years; P\ .001). The pro-
portion of patients age 60-65 years was 74% in the
transplantation group and 58% in the chemotherapy
group (P 5 .022). There were no significant between-
group differences in sex distribution, proportion
of therapy-related leukemia, white blood cell count
at diagnosis, French-American-British subtype, orproportions of patients with favorable, normal,
intermediate-II, or adverse-risk karyotypes. Time from
diagnosis to achievement of CR1 was longer in the
transplantation group (median, 38 days vs 44 days;
P 5 .031). The median follow-up from the date of
CR1 was 44 months for the transplantation group and
51 months for the chemotherapy group.
In the chemotherapy group, 69% of patients re-
ceived consolidation therapy on a CALGB protocol
at a median of 55 days (range, 1-98 days) after achiev-
ing CR1. In those receiving consolidation therapy,
the performance status was Eastern Cooperative
OncologyGroup (ECOG) 1 in 78%, ECOG2 in 20%,
and ECOG 3 in 2%. The proportion of patients in the
transplantation group who received consolidation
treatment before allogeneicHCT is unknown, because
the details of postremission therapy were not consis-
tently captured for this group.
In the transplantation group, donors were HLA-
identical siblings in 47% of cases, well-matched (at least
HLA-A, -B, and -DRB1 bymolecular typing) unrelated
donors in 30% of cases, and partially matched or
unknown in the remaining cases (Table 1). In 93% of
transplantations, the stem cell source was peripheral
blood. Preparative regimens generally combinedfludar-
abine with melphalan (n 5 23), busulfan (n 5 24),
low-dose (200 cGy)TBI (n5 25), or cyclophosphamide
(n5 12). GVHD prophylaxis included cyclosporine or
tacrolimus in combinations with methotrexate in 31
patients, and cyclosporine or tacrolimus in 60 patients.
Nonrelapse Mortality
The cumulative incidence of death in CR1 from
causes other than relapsed AML was significantly
lower in the chemotherapy group (P \ .001)
(Figure 1). At 3 years, the cumulative incidence of non-
relapse mortality was 4% (95% CI, 1%-9%) in the
chemotherapy group, compared with 36% (95% CI,
26%-46%) in the transplantation group. The specific
causes of nonrelapse deaths in the chemotherapy
group were not available. The most common causes
of nonrelapse deaths in the transplantation group
were infection (n 5 14, including 8 with acute or
chronic GVHD); GVHD (n 5 7), pneumonitis/adult
respiratory distress syndrome (n5 5), and hemorrhage
or other regimen-related toxicity (n 5 15).
Cumulative Incidence of Relapse
As shown in Figure 2, the risk of relapse was signif-
icantly higher in the chemotherapy group (P\ .001).
This group had a cumulative incidence of relapse at
3 years of 81% (95% CI, 71%-87%), compared with
32% (95% CI, 22%-42%) for the transplantation
group. Although few patients had favorable karyotypic
abnormalities, allogeneic HCT appeared to be associ-
ated with lower cumulative incidence of relapse across
Table 1. Patient and Transplantation Characteristics
HCT (n 5 94) Chemotherapy (n 5 96) P Value
Patient characteristics
Age (years), median (range) 63 (60-70) 65 (60-70) <.001
Age distribution, n (%) .022
60-65 years 70 (74) 56 (58)
66-70 years 24 (26) 40 (42)
Male, n (%) 55 (59) 55 (57) 0.88
White blood cell count at diagnosis ( 109/L), median (range)* 5.9 (0.5-216.0) 5.6 (0.8-191.7) .72
French-American-British classification, n (%)†
M0 9 (10) 3 (6)
M1 22 (23) 7 (13)
M2 25 (27) 14 (26)
M4 11 (12) 16 (30)
M5 10 (11) 8 (15)
M6 3 (3) 2 (4)
M7 1 (1) 0 (0)
Unclassified 13 (14) 4 (7)
Therapy-related AML, n (%) 10 (11) 7 (7) .46
Cytogenetics, n (%)‡ .32
Favorable 2 (2) 8 (8)
Normal 44 (56) 52 (55)
Intermediate-II 15 (19) 20 (21)
Adverse 17 (22) 15 (16)
Time from diagnosis to CR1 (days), median (range) 44 (10-251) 38 (24-211) .031
Transplantation-related characteristics
Time from diagnosis to transplantation (days), median (range) 189 (63-828) NA
Time from CR1 to transplantation, n (%) NA
<120 days 39 (41)
120-180 days 28 (30)
181-270 days 20 (21)
>270 days 7 (7)
Karnofsky score at transplantation $90% (n) 63 NA
Preparative regimen including, n (%) NA
Melphalan #150 mg/m2 (± other) 23 (24)
Busulfan # 9 mg/kg (± other) 24 (26)
Fludarabine + TBI 200 cGy 23 (25)
Fludarabine + cyclophosphamide 12 (13)
Total lymphoid irradiation + antithymocyte globulin 5 (5)
TBI 200 cGy 2 (2)
TBI (<500 cGy single dose or <800 cGy fractionated dose) 3 (3)
Other 2 (2)
GVHD prophylaxis, n (%) NA
Cyclosporine A or tacrolimus + methotrexate ± other 31 (33)
Cyclosporine A or tacrolimus ± other 60 (64)
T cell depletion 3 (3)
Donor type, n (%) NA
HLA-identical sibling 44 (47)
Other related 5 (5)
HLA-matched unrelated 28 (30)
Partially matched unrelated 12 (13)
Mismatched unrelated 2 (2)
Unrelated (matching unknown) 3 (3)
Graft type, n (%) NA
Bone marrow 7 (7)
Peripheral blood ± bone marrow 87 (93)
NA indicates not applicable.
*White blood cell count at presentation was unknown for 10 patients in the transplantation group and for 13 patients in the chemotherapy group.
†French-American-British classification was unknown for 42 patients in the chemotherapy group.
‡Intermediate-II and adverse cytogenetic categories as described elsewhere [21]. Favorable includes t(8;21)(p22;q22), inv(16)(p13.1q22), or
t(16;16)(p13.1;q22).
Biol Blood Marrow Transplant 17:1796-1803, 2011 1799Allogeneic HCT in Older Patients with AMLall cytogenetic subgroups (P \ .001 for overall test;
Table 2). The relative risk (RR) of relapse after chemo-
therapy was significantly worse than that after HCT
(RR: 3.47; 95% CI: 2.26-5.34; P\ .0001).
LFS
Figure 3 shows a significantly shorter LFS in the
chemotherapy group compared with the transplanta-tion group HCT (P 5 .001). The median LFS for
HCT patients was 15.7 months for the transplantation
group and 8.5 months for the chemotherapy group.
The 3-year LFS was 32% (95% CI: 23%-42%)
for the transplantation group, compared with 15%
(95% CI: 9%-23%) for the chemotherapy group
(Figure 3). Importantly, patients in all karyotypic sub-
groups appeared to have improved LFS with HCT
Figure 1. Cumulative incidence of nonrelapse death in CR1.
Table 2. Estimated 3-Year Incidence of Relapse, LFS, and OS
by Cytogenetic Risk Group*
HCT Chemotherapy P value
Cumulative incidence of relapse <.001
Favorable karyotype 0 69 (38-93)
Normal 33 (20-47) 79 (68-88)
Intermediate-II 25 (6-51) 90 (76-98)
Adverse karyotype 45 (23-68) 80 (60-94)
LFS .001
Favorable karyotype 100 (100-100) 19 (0-57)
Normal 39 (24-55) 17 (8-28)
Intermediate-II 30 (9-57) 10 (1-27)
Adverse 22 (6-44) 13 (1-35)
OS .08
Favorable karyotype 100 (100-100) 50 (18-82)
Normal 45 (30-61) 27 (16-39)
Intermediate-II 32 (10-59) 23 (7-45)
Adverse 23 (7-45) 13 (1-35)
Values are the 3-year estimates (95% CI) for the endpoints shown.
P value comparisons within these small cytogenetic subsets are not
presented because of the small numbers. P values represent the overall
adjusted comparisons between the transplantation and chemotherapy
groups.
*Definitions of cytogenetic risk groups in the favorable and normal cyto-
genetic categories did not take into account molecular results.
1800 Biol Blood Marrow Transplant 17:1796-1803, 2011S. S. Farag et al.compared with chemotherapy (Table 2). The RR of
death or relapse after chemotherapy compared with af-
ter HCT was 1.72 (95% CI: 1.23-2.41; P 5 .0014).
OS
OS was longer in the transplantation group,
although the difference bewteen groups was not statis-
tically significant (P5 .08) (Figure 4). The median OS
was 20.1 months for the transplantation group and
15.7 months for the chemotherapy group, and the
respective 3-year OS was 37% (95% CI: 27%-47%)
and 25% (95% CI: 17%-34%). OS was better in the
transplantation group across all karyotype subgroups
(Table 2). The RR of death after chemotherapy com-
pared with after HCT was 1.35 (95% CI: 0.97-1.89,
P 5 .076).
Transplantation-Specific Outcomes
In the 94 patients who received allogeneic HCT in
CR1, engraftment occurred in 94% (95% CI: 88%-
98%) by 28 days posttransplantation. The cumulative
incidence of grade II-IV acute GVHD at 1 year was
39% (95% CI: 30%-49%), and that of chronic
GVHD at 3 years was 39% (95% CI: 30%-50%).DISCUSSION
Our results indicate that RIC allogeneic HCT
performed in CR1 for patients with AML ageFigure 2. Cumulative incidence of relapse.60-70 years is associated with a significantly lower re-
lapse rate and superior LFS compared with treatment
with chemotherapy alone. These favorable results
appeared to occur in all cytogenetic subgroups. Our
findings suggest that a GVL effect may be operative
after RIC HCT in older patients with AML, and that
a sizeable fraction of older patients under age 70 can
benefit from the antileukemic effect of HCT.
To date, no prospective trials comparing RIC allo-
geneic HCT and chemotherapy have been reported.
Patient and physician biases and limited healthy
sibling donor availability might confound the develop-
ment of such a trial [18]. Indeed, randomization to
include unrelated or umbilical cord blood donors
requires a complete donor search, which is an involved
process that is not undertaken unless an allograft is be-
ing actively considered by both the patient and the
treating physician. Several previous studies of RIC
allogeneic HCT in older patients with AML have sug-
gested significantly better survival after transplanta-
tion in CR1 [12,25-27]. Although these studiesFigure 3. LFS.
Figure 4. OS.
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patients with AML are encouraging, they generally
included only small numbers of patients age 60 and
older and often included patients beyond CR1.
These older patients might be highly selected for
their interest and fitness to undergo allografting.
Indeed, in a recent analysis assessing the feasibility of
allogeneic HCT in patients age 50 and older with
AML (and high-risk myelodysplasia), only 14 of 259
patients eventually underwent transplantation in
CR1 [28], demonstrating the difficulty of identifying
and promptly evaluating older patients who might be
candidates for allogeneic HCT.
In this report, we include comparisons with pa-
tients who met eligibility criteria for enrollment on
CALGB trials, reflecting at least some similar selection
criteria albeit at the time of diagnosis, some months
before assessing fitness for HCT. Despite our attempt
to include comparable patients in the 2 cohorts, how-
ever, we acknowledge that some important differences
exist. For example, in the chemotherapy group,
patients who underwent allogeneic HCT in their
subsequent disease course either in CR or as salvage
for relapse were excluded from the analysis. However,
given that the proportion of older patients with AML
who typically proceed to transplantation is expected
to be very low [28], particularly after initial relapse,
we believe that the impact of excluding patients who
later underwent transplantation from the chemotherapy-
only group is likely to be minimal. In addition, in the
present analysis, patients undergoing allogeneic
HCT in CR1 could have received multiple lines of
therapy to achieve remission, but only those patients
who achieved CR1 after no more than 2 courses of
induction were included in the chemotherapy group.
The difference in definition of CR1 between the
2 groups in this analysis, however, is likely to bias
against the outcome of the allogeneic HCT cohort,
because patients who achieve CR1 after more than 2
courses of chemotherapy might be expected to have
more resistant leukemia compared with those who
achieve CR1 after only 1 or 2 courses of induction che-
motherapy. Notwithstanding these differences, ourobservations demonstrating the superiority of RIC
allogeneic HCT over chemotherapy in these older
patients with AML remain clear.
We compared allogeneic HCT with chemother-
apy in a sizeable number of older patients with AML.
To minimize the effect of selection and lead-time
bias, we restricted our comparison to chemotherapy-
treated patients who remained in CR1 for at least
4 months, given that those with very early relapse
would not be considered for transplantation [29]. A
previous donor versus no-donor analysis of 95 patients
with AML in CR1 with sibling donors demonstrated
significantly better LFS and OS for the patients with
a donor, suggesting that RIC allogeneic HCT in
CR1 is superior to chemotherapy alone [28]. However,
that study had a preponderance of patients under
age 60 years, many of whom also received high-dose
cytarabine or autologous stem cell transplantation
consolidation before allogeneic HCT, thus limiting
comparisons with our results.
Despite higher nonrelapse mortality, our findings
demonstrate that allogeneic HCT in CR1 led to a sig-
nificant reduction in relapse and improvement in LFS.
It should be noted, however, that our study does not
exclude a potential improvement in OS given its lim-
ited statistical power of only 37% to demonstrate a
statistically significant difference of 12% for OS at
3 years. We estimate that a study would require
250 patients in each group to have 80% power to dem-
onstrate this difference in 3-year OS. Nonetheless, our
results suggest that strategies aimed at reducing nonre-
lapse mortality associated with allogeneic HCT could
yield further improvements. The incorporation of an-
tithymocyte globulin or other in vivo T cell–depleting
antibodies might limit the morbidity of acute GVHD
and decrease nonrelapse mortality [25], although it
could possibly increase the risk of relapse [30]. More
recently, promising results from GVHD prophylaxis
using sirolimus plus tacrolimus have been reported
[31,32], and this is currently under study in the Blood
and Marrow Transplant Clinical Trials Network.
Although HCT led to a significant reduction in re-
lapse apparently in all cytogenetic subgroups, relapse
remains a significant cause of treatment failure after al-
logeneicHCT in older patients with AML. Indeed, our
observed relapse risk is similar to that reported by other
investigators after RIC allogeneic HCT [25,28,29].
Several strategies to reduce relapse may improve the
efficacy of RIC allogeneic HCT, including the
investigation of novel preparative regimens, such as
the use of clofarabine with alkylating agents (as
recently tested in the myeloablative setting with
promising results [33]), use of hypomethylating agents
before or after allogeneic HCT [34,35], and immune-
based strategies, such as preemptive donor lymphocyte
infusions [36] and vaccination against leukemia-specific
antigens [37].
1802 Biol Blood Marrow Transplant 17:1796-1803, 2011S. S. Farag et al.We conclude that RIC allogeneic HCT in patients
age 60-70 years with AML is feasible and associated
with a significant reduction in relapse and improve-
ment in long-term outcome. Earlier referral for trans-
plantation along with strategies directed at limiting
nonrelapse mortality, including better GVHD pro-
phylaxis and treatment, may improve these outcomes
for an even greater proportion of older patients with
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